Minerva Neurosciences, Inc. (NERV)
NERV Stock Price Chart
Explore Minerva Neurosciences, Inc. interactive price chart. Choose custom timeframes to analyze NERV price movements and trends.
NERV Company Profile
Discover essential business fundamentals and corporate details for Minerva Neurosciences, Inc. (NERV) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
1 Jul 2014
Employees
8.00
CEO
Remy Luthringer
Description
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
NERV Financial Timeline
Browse a chronological timeline of Minerva Neurosciences, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 23 Feb 2026
Upcoming earnings on 4 Nov 2025
EPS estimate is -$0.35.
Earnings released on 14 Aug 2025
EPS came in at -$0.43 surpassing the estimated -$0.95 by +54.74%.
Earnings released on 13 May 2025
EPS came in at -$0.50 surpassing the estimated -$1.07 by +53.27%.
Earnings released on 25 Feb 2025
EPS came in at -$0.56 surpassing the estimated -$1.05 by +46.67%, while revenue for the quarter reached $42.22K .
Earnings released on 5 Nov 2024
EPS came in at $2.97 surpassing the estimated -$1.01 by +394.06%.
Earnings released on 6 Aug 2024
EPS came in at -$1.09 falling short of the estimated -$0.97 by -12.37%.
Earnings released on 1 May 2024
EPS came in at -$1.13 surpassing the estimated -$1.20 by +5.83%.
Earnings released on 22 Feb 2024
EPS came in at -$1.19 falling short of the estimated -$0.88 by -35.23%.
Earnings released on 7 Nov 2023
EPS came in at -$1.03 falling short of the estimated -$0.77 by -33.77%.
Earnings released on 1 Aug 2023
EPS came in at -$1.12 falling short of the estimated -$0.44 by -154.55%.
Earnings released on 15 May 2023
EPS came in at -$1.31 surpassing the estimated -$1.63 by +19.63%.
Earnings released on 8 Mar 2023
EPS came in at -$1.26 surpassing the estimated -$1.35 by +6.67%.
Earnings released on 9 Nov 2022
EPS came in at -$1.29 surpassing the estimated -$1.46 by +11.64%.
Earnings released on 9 Aug 2022
EPS came in at -$1.63 surpassing the estimated -$1.84 by +11.41%.
Stock split effective on 21 Jun 2022
Shares were split 1 : 8 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 4 May 2022
EPS came in at -$1.84 falling short of the estimated -$1.60 by -15.00%.
Earnings released on 1 Mar 2022
EPS came in at -$0.96 surpassing the estimated -$1.60 by +40.00%.
Earnings released on 8 Nov 2021
EPS came in at -$1.76 matching the estimated -$1.76.
Earnings released on 2 Aug 2021
EPS came in at -$2.00 falling short of the estimated -$1.36 by -47.06%.
Earnings released on 12 May 2021
EPS came in at -$1.68 falling short of the estimated $1.60 by -205.00%.
Earnings released on 8 Mar 2021
EPS came in at -$1.36 surpassing the estimated -$1.68 by +19.05%, while revenue for the quarter reached $0.04 .
Earnings released on 2 Nov 2020
EPS came in at -$1.52 surpassing the estimated -$1.76 by +13.64%.
NERV Stock Performance
Access detailed NERV performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.